BACKGROUND: Seizures are common in critically ill patients and can impact morbidity and mortality. Traditional anti-epileptic drugs (AEDs) in this setting are not always effective and are associated with adverse events and drug interactions. Lacosamide (LCM) is a new AED which is available in parental form although few studies have evaluated the safety and efficacy of LCM in critically ill patients. METHODS: Critically ill patients at Emory University Hospital who received LCM from April 1, 2009 to February 1, 2010 were retrospectively reviewed. Primary outcome measure was incidence and time to seizure cessation. Adverse effects were also recorded. RESULTS: LCM was administered in 24 patients including 13 episodes of refractory status epilepticus (RSE) occurring in 10 patients and for treatment of isolated seizures or following resolution of RSE in an additional 14 patients. Seizure cessation was achieved in 5/13 (38%) episodes of RSE (mean 11.2 h) while there was at least a 50% decrease in seizure frequency in 7/13 (54%). 11/14 patients (76%) who received LCM for treatment of isolated seizures or prevention of seizure recurrence remained seizure free. Three patients experienced a decline in systolic blood pressure (> 20 mmHg) while one patient experienced unexplained fever and one patient had elevation of liver function tests. CONCLUSIONS: This preliminary data suggests that LCM may be a safe and effective alternative for treatment of seizures in critically ill patients. Further prospective, randomized controlled trials are needed to confirm these findings and further explore the incidence of adverse effects.
BACKGROUND:Seizures are common in critically illpatients and can impact morbidity and mortality. Traditional anti-epileptic drugs (AEDs) in this setting are not always effective and are associated with adverse events and drug interactions. Lacosamide (LCM) is a new AED which is available in parental form although few studies have evaluated the safety and efficacy of LCM in critically illpatients. METHODS:Critically illpatients at Emory University Hospital who received LCM from April 1, 2009 to February 1, 2010 were retrospectively reviewed. Primary outcome measure was incidence and time to seizure cessation. Adverse effects were also recorded. RESULTS:LCM was administered in 24 patients including 13 episodes of refractory status epilepticus (RSE) occurring in 10 patients and for treatment of isolated seizures or following resolution of RSE in an additional 14 patients. Seizure cessation was achieved in 5/13 (38%) episodes of RSE (mean 11.2 h) while there was at least a 50% decrease in seizure frequency in 7/13 (54%). 11/14 patients (76%) who received LCM for treatment of isolated seizures or prevention of seizure recurrence remained seizure free. Three patients experienced a decline in systolic blood pressure (> 20 mmHg) while one patient experienced unexplained fever and one patient had elevation of liver function tests. CONCLUSIONS: This preliminary data suggests that LCM may be a safe and effective alternative for treatment of seizures in critically illpatients. Further prospective, randomized controlled trials are needed to confirm these findings and further explore the incidence of adverse effects.
Authors: Kimberly A Parkerson; Claus Reinsberger; Sherry H Chou; Barbara A Dworetzky; Jong Woo Lee Journal: Epilepsy Behav Date: 2010-11-19 Impact factor: 2.937
Authors: J Claassen; N Jetté; F Chum; R Green; M Schmidt; H Choi; J Jirsch; J A Frontera; E Sander Connolly; R G Emerson; S A Mayer; L J Hirsch Journal: Neurology Date: 2007-09-25 Impact factor: 9.910
Authors: Paul M Vespa; Chad Miller; David McArthur; Mathew Eliseo; Maria Etchepare; Daniel Hirt; Thomas C Glenn; Neil Martin; David Hovda Journal: Crit Care Med Date: 2007-12 Impact factor: 7.598
Authors: P M Vespa; K O'Phelan; M Shah; J Mirabelli; S Starkman; C Kidwell; J Saver; M R Nuwer; J G Frazee; D A McArthur; N A Martin Journal: Neurology Date: 2003-05-13 Impact factor: 9.910
Authors: Victor Biton; William E Rosenfeld; John Whitesides; Nathan B Fountain; Nerija Vaiciene; G David Rudd Journal: Epilepsia Date: 2007-09-19 Impact factor: 5.864
Authors: Aatif M Husain; Jong W Lee; Bradley J Kolls; Lawrence J Hirsch; Jonathan J Halford; Puneet K Gupta; Yafa Minazad; Jennifer M Jones; Suzette M LaRoche; Susan T Herman; Christa B Swisher; Saurabh R Sinha; Adriana Palade; Keith E Dombrowski; William B Gallentine; Cecil D Hahn; Elizabeth E Gerard; Manjushri Bhapkar; Yuliya Lokhnygina; M Brandon Westover Journal: Ann Neurol Date: 2018-06 Impact factor: 10.422
Authors: Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk Journal: Ther Adv Neurol Disord Date: 2016-11-29 Impact factor: 6.570
Authors: David G Vossler; Jacquelyn L Bainbridge; Jane G Boggs; Edward J Novotny; Tobias Loddenkemper; Edward Faught; Marta Amengual-Gual; Sarah N Fischer; David S Gloss; Donald M Olson; Alan R Towne; Dean Naritoku; Timothy E Welty Journal: Epilepsy Curr Date: 2020-08-21 Impact factor: 7.500
Authors: Ylse Gutiérrez-Grobe; Jose Antonio Bahena-Gonzalez; Magali Herrera-Gomar; Pedro Mendoza-Diaz; Sandra García-López; Octavio González-Chon Journal: Case Rep Emerg Med Date: 2013-08-20